Novavax told investors there is uncertainty surrounding the company\u0027s ability to continue operating as the vaccine market shifts. Read on.
The company, which has more than $1.3 billion in cash on hand, is counting on its ability to develop and sell an updated COVID-19 vaccine next fall and is cutting costs, Kelly told investors.
However, on an NRC website last updated in December, the federal science and technology agency said it is still working on the “technology transfer” required to produce the vaccine.Article content“Novavax continues to make progress towards establishing local manufacturing capabilities in partnership with NRC/, with manufacturing of process performance qualification batches expected to begin in early 2023,” the company said.
“We’re continuing to explore options with potential collaborators on producing vaccines and other biologics at the facility on its second production line,” Christine Jodoin, the vice-president of strategic initiatives at the NRC, wrote in an email.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Company planning to make COVID-19 vaccines in Canada warns it could go out of businessNovavax executives told investors there is significant uncertainty surrounding the company’s ability to continue funding operations as the market for COVID-19 vaccines changes
Lire la suite »
Company planning to make COVID-19 vaccine in Canada could go out of businessAn American company that signed a deal with the federal government to produce COVID-19 vaccines in Montreal is warning investors it could go out of business within the year.
Lire la suite »
Company planning to make COVID-19 vaccine in Canada could go out of businessMONTREAL — An American company that signed a deal with the federal government to produce COVID\u002D19 vaccines in Montreal has warned investors it could go out of…
Lire la suite »
Novavax shares slump after COVID-19 vaccine maker raises doubts about futureNovavax on Tuesday flagged significant uncertainty around its 2023 revenue, funding from the U.S. government and pending arbitration with global vaccine alliance Gavi
Lire la suite »
Novavax shares plunge after COVID-19 vaccine maker raises doubts over its future - National | Globalnews.caNovavax — whose COVID-19 vaccine is its only marketed product after 35 years in business — on Tuesday flagged significant uncertainty around its 2023 revenue.
Lire la suite »
Everything Coming to Netflix Canada in March 2023 | Elle CanadaFrom season 2 of nextinfashion to MurderMystery 2 starring JenniferAniston and AdamSandler, here's everything coming to netflix Canada this month.
Lire la suite »